e-learning
resources
Copenhagen 2005
Monday 19.09.2005
Novel therapies for asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
As-needed treatment with a β
2
-agonist or a β
2
-agonist/ corticosteroid combination in mild intermittent asthma (SOMA)
T. Haahtela, K. Tamminen, P. Malmberg, J. Karjalainen, H. Ylä-Outinen, O. Zetterström, T. Ekström, O. Selroos (Helsinki, Finland; , ; Linköping, Sweden)
Source:
Annual Congress 2005 - Novel therapies for asthma
Session:
Novel therapies for asthma
Session type:
Poster Discussion
Number:
1722
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Haahtela, K. Tamminen, P. Malmberg, J. Karjalainen, H. Ylä-Outinen, O. Zetterström, T. Ekström, O. Selroos (Helsinki, Finland; , ; Linköping, Sweden). As-needed treatment with a β
2
-agonist or a β
2
-agonist/ corticosteroid combination in mild intermittent asthma (SOMA). Eur Respir J 2005; 26: Suppl. 49, 1722
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 615s
Year: 2007
Adding slow-released theophyllne to inhaled corticosteroids in the treatment of mild persistent asthma
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007
Budesonide–formoterol reliever therapy in intermittent
versus
mild persistent asthma
Source: Eur Respir J, 57 (2) 2003064; 10.1183/13993003.03064-2020
Year: 2021
Comparison of the efficacy of cicleosonide with budesonide in mild to moderate asthma patients after step-down therapy
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Intermittent therapy with budesonide/formoterol in children with moderate asthma.
Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities
Year: 2017
Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting
2
-agonists (LABA) in moderately severe COPD
Source: Annual Congress 2011 - Disease management in specific primary care populations
Year: 2011
Oral corticosteroids in the treatment of exacerbation of severe asthma
Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden
Year: 2020
The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004
Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid
Source: Eur Respir J 2002; 20: Suppl. 38, 113s
Year: 2002
Nebulizer therapy with budesonide in addition to systemic corticosteroids in acute severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 541s
Year: 2004
Budesonide/formoterol for maintenance and relief
vs.
higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007
Comparison of inhaled corticosteroid combined with theophylline and double-dose inhaled corticosteroid in moderate-severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 127s
Year: 2004
Novel combination inhaler for mild asthma treatment
Source: Annual Congress 2008 - Asthma control or asthma severity
Year: 2008
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Source: Eur Respir J 2008; 32: 1237-1242
Year: 2008
The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA)
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
Suboptimal persistence with inhaled corticosteroid (ICS) mono-therapy among children with persistent asthma in the UK
Source: Eur Respir J 2006; 28: Suppl. 50, 709s
Year: 2006
LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015
Children with mild asthma: do they benefit from inhaled corticosteroids?
Source: Eur Respir J 2002; 20: 1470-1475
Year: 2002
Withdrawal of high-dose inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: a feasibility study in primary care.
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept